Lilly, Purdue seek medical advancements in new $52M collaboration
Eli Lilly and Co. announced the “strategic research collaboration” Thursday morning, calling it the largest agreement of its kind between Purdue and a single company.
Eli Lilly and Co.
Articles
Performance gap widening in some generic drugs, researchers say
As medicines—especially those that treat conditions such as anxiety or depression—are becoming more complex, it’s not just the mix of active ingredients that generic drugmakers have to replicate. It’s also the release mechanism.
Lilly, Pfizer get boost for non-opioid pain drug
The companies say the drug, now in late-stage clinical trials, could be more effective for pain treatment than opioids—a dangerous category of pain killers that includes hydrocodone, morphine and fentanyl—without the abuse potential of such medications.
Nevada forces drugmakers to reveal insulin pricing, profits
America's three insulin manufacturers—Indianapolis-based Eli Lilly and Co., Sanofi and Novo Nordisk—would face fines of $5,000 daily if they fail to provide the data.
First bellwether trial for ‘low-T’ treatment could have ramifications for Lilly
A set of consolidated lawsuits accuse AbbVie and other makers of testosterone-replacement medicines, including Eli Lilly and Co., of hiding or downplaying their products’ risk for blood clots or other serious injuries.
Lilly CFO Derica Rice to leave company in December
Rice, 52, who had been the company's top finance officer since 2006, is one of the most powerful black executives in corporate America. He had been widely considered a leading candidate to succeed CEO John Lechleiter, but that position went to fellow Lilly executive Dave Ricks.
Lilly hires ‘powerhouse’ D.C. lobbyist
Leigh Ann Pusey will join Eli Lilly and Co. next month as senior vice president for corporate affairs and communications.
Lilly migraine drug provides relief in late-stage trials
Lilly is in a race with several pharmaceutical firms to develop migraine treatments using an approach known as anti-CGRP and that could create a multibillion-dollar market.
Drug lobby mulling membership reductions amid price scrutiny
The lobby group, Pharmaceutical Research and Manufacturers of America—which counts Eli Lilly and Co. as a member—is proposing that to remain a member, companies will have to spend $200 million a year on research and development.
Lilly executive Pescovitz leaving to become university president
Oakland University in suburban Detroit on Thursday announced that its board of trustees unanimously chose Ora Hirsch Pescovitz for the job after a search involving more than 60 candidates.
Despite setbacks, top Lilly researcher bullish on pipeline’s momentum
The Indianapolis drugmaker is trying to reassure Wall Street that its pipeline is still poised to deliver.
Lilly diabetes drug Jardiance falls short of quarterly sales predictions
Shares in Eli Lilly and Co. stock fell more than 3 percent Tuesday after the Indianapolis-based drugmaker released a quarterly earnings report that showed sales of potential blockbuster drug Jardiance missed expectations by a wide margin.
Lilly profit climbs 18 percent after one-time expenses
The Indianapolis-based drugmaker beat Wall Street expectations by 2 cents a share—performance it attributed to brisk sales of new products.
Lilly uses ‘horny goat weed’ to fend off Cialis royalty demands
Eli Lilly and Co. told a federal jury that a German company is trying to take credit for centuries-old Chinese medicine in seeking royalties on the use of its erectile-dysfunction drug Cialis to treat an enlarged prostate.
Lilly’s rheumatoid arthritis pill rejected by regulators
The drug, which has the proposed brand name Olumiant and is approved for use in Europe, was expected to be a big seller.
Blame game over drug prices escalates with new ad campaign
Broadening its efforts to defuse outrage over skyrocketing prices, the pharmaceutical industry’s lobbying association has started an advertising campaign urging insurers to share with customers more of the benefits of rebates they’ve negotiated.
Lilly among firms pulling ads from ‘O’Reilly Factor’
A sexual harassment scandal involving host Bill O’Reilly has prompted major advertisers such as Eli Lilly and Co. and several automakers to drop out. Indianapolis-based Angie’s List is among those sticking with the show.
Lilly CEO Ricks stands to make about $12M in first year at helm
Dave Ricks joined Lilly in 1996 and most recently served as president of Lilly Bio-Medicines. He took over as president and CEO on Jan. 1.
Eli Lilly chasing psoriasis jackpot with Taltz
Taltz, which hit the market last year, is taking on an armful of older treatments, including creams, lotions, pills and injectables, such as Amgen’s Enbrel and AbbVie’s Humira.
Pharma stocks slide after new tweet from Trump on drug prices
Share of Eli Lilly and Co. and numerous other drug industry stocks fell Tuesday morning after the president sent a tweet promising to lower medicine costs for American people.